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Abstract
Despite decades of research aimed at identifying the causes of postpartum depression (PPD), PPD 
remains common, and the causes are poorly understood. Many have attributed the onset of PPD to 
the rapid perinatal change in reproductive hormones. Although a number of human and non-
human animal studies support the role of reproductive hormones in PPD, several studies have 
failed to detect an association between hormone concentrations and PPD. The purpose of this 
review is to examine the hypothesis that fluctuations in reproductive hormone levels during 
pregnancy and the postpartum period trigger PPD in susceptible women. We discuss and integrate 
the literature on animal models of PPD and human studies of reproductive hormones and PPD. We 
also discuss alternative biological models of PPD to demonstrate the potential for multiple PPD 
phenotypes and to describe the complex interplay of changing reproductive hormones and 
alterations in thyroid function, immune function, HPA axis function, lactogenic hormones, and 
genetic expression that may contribute to affective dysfunction. There are three primary lines of 
inquiry that have addressed the role of reproductive hormones in PPD: non-human animal studies, 
correlational studies of postpartum hormone levels and mood symptoms, and hormone 
manipulation studies. Reproductive hormones influence virtually every biological system 
implicated in PPD, and a subgroup of women seem to be particularly sensitive to the effects of 
perinatal changes in hormone levels. We propose that these women constitute a “hormone-
sensitive” PPD phenotype, which should be studied independent of other PPD phenotypes to 
identify underlying pathophysiology and develop novel treatment targets.
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Despite decades of research aimed at identifying the causes of postpartum depression (PPD) 
and developing effective methods of screening, prevention, and treatment, PPD remains 
common, affecting between 7 and 20% of women following delivery1. PPD is one of the 
most important public health problems that we can address: it not only affects women at a 
highly vulnerable time, but it also has deleterious effects on children and families. Many 
have speculated that PPD is caused, at least in part, by the rapid change in the reproductive 
hormones estradiol and progesterone before and immediately after delivery2. Although a 
number of human and non-human animal studies suggest that changes in reproductive 
hormone levels contribute to PPD3–8, several studies have failed to detect an association 
between hormone concentrations and PPD symptoms9–11. For example, cross-sectional 
human studies examining between-group differences in ovarian hormones levels and 
depressive symptoms during the postpartum period have failed to demonstrate and 
association between absolute estrogen and progesterone concentrations and PPD9–11. In 
contrast, studies that have treated PPD with estradiol have successfully reduced depressive 
symptoms5,12, and animal studies have demonstrated that estradiol and progesterone 
withdrawal provoke depression-like behavior4,7,8.
The mixed results regarding the role of estradiol and progesterone in PPD is likely due to 
three factors. First, the PPD diagnosis contains enormous variability. A postpartum 
depressive episode can meet the diagnostic criteria in a number of different ways, which 
results in women with very different symptom presentations receiving the same diagnosis. 
Two women could share only one symptom of major depression, experience timing of onset 
of the episode during very different hormonal conditions (e.g., first trimester of pregnancy 
versus first week postpartum), and both receive a PPD diagnosis. Thus, PPD likely 
represents a number of depressive phenotypes, which may in large part account for the 
difficulty in identifying any biological or hormonal factor central to the disorder.
Second, based on epidemiologic studies of risk, social and psychological factors play a large 
role in the pathogenesis of PPD. For example, decreased social support, poor quality social 
support, and poor marital satisfaction increase the risk of PPD13–15. The number of previous 
episodes of depression, a history of PPD, and depression during pregnancy are also 
significant risk factors for PPD15–17. PPD, like any mood disorder, is therefore best seen as 
a clinical integration of risk and protective factors that culminate in the triggering of a mood 
episode in the context of a biological (or reproductive) state.
Third, the existing studies have used widely diverging methods to examine how 
reproductive hormones influence depressive symptoms: some have examined absolute 
hormone concentrations in those with and without the disorder9–11, some have examined the 
change in hormone levels during pregnancy and the immediate postpartum period and the 
attendant changes in depressive symptoms10,18, some have administered hormones to well 
individuals at high risk for PPD3, and some have used hormones as a treatment for PPD5,12. 
Any biological model of PPD has to account for all three of these problems.
The purpose of this review is to examine the evidence for a reproductive hormone model of 
PPD in which fluctuating reproductive hormone levels trigger affective dysregulation. We 
will define PPD and discuss the diagnostic issues that contribute to difficulties in identifying 
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a single biomarker for the disorder. We will discuss alternative biological models of PPD to 
demonstrate the potential for multiple PPD phenotypes and to describe the complex 
interplay of changing reproductive hormones and alterations in thyroid function, immune 
function, HPA axis function, lactogenic hormones, and genetic expression that may 
contribute to affective dysfunction. We will present animal models and human studies of 
reproductive hormones and PPD and discuss methodological issues that have contributed to 
conflicting findings in the literature. We will provide evidence of a “hormone-sensitive” 
PPD phenotype, and discuss the potential neurobiological pathophysiology of PPD for this 
group of women. Finally, we will review human brain imaging and genetic studies as they 
pertain to the hormonal contribution to affective dysregulation during the perinatal period.
Defining PPD
The DSM-5 expanded the definition of PPD to include major depressive episodes with a 
perinatal onset as those beginning in either pregnancy or within the first four weeks 
postpartum19. Although PPD and non-perinatal major depressive disorder have the same 
DSM diagnostic criteria (i.e., depressed mood, anhedonia, sleep and appetite disturbance, 
impaired concentration, psychomotor disturbance, lethargy, feelings of worthlessness or 
guilt, and suicidal ideation)19, the symptoms of psychomotor agitation and lethargy are more 
prominent in PPD than MDD20. Additional symptoms of PPD include mood lability and 
preoccupation with infant well-being. PPD also is frequently associated with symptoms of 
anxiety, ruminative thoughts, and panic attacks21. Indeed, most women with PPD have 
comorbid anxiety disorders21. Recent estimates suggest that 7% of women experience an 
episode of major depression in the first three months following delivery, and the prevalence 
increases to 20% when episodes of minor depression are also included1. The majority of 
existing studies suggest that PPD is no more common than non-postpartum depression22; 
however, the largest epidemiological study to date demonstrated an increased risk of 
depression during the postpartum period23.
PPD is distinguished from the postpartum blues, which are defined as normative “mild 
dysphoria occurring in the first week after delivery”22. Also distinct from PPD is postpartum 
psychosis, which has a rapid onset associated with hallucinations or bizarre delusions, mood 
swings, disorganized behavior, and cognitive impairment24,25. Many cases of postpartum 
psychosis are manifestations of bipolar disorder26,27, which may present as mania for the 
first time during the postpartum period. The perturbation in mood, limited reality testing, 
and gross functional impairment make postpartum psychosis particularly dangerous for 
mothers and babies24.
An important limitation of the DSM criteria for PPD is that it is not mechanistically based, 
which is why the National Institute of Mental Health (NIMH) Research Domain Criteria 
(RDoC) project may be an ideal framework for studying PPD. The RDoC project advocates 
study of basic dimensions of functioning (e.g., emotion processing) across multiple units of 
analysis (e.g., genetic risk and epigenetic modification, limbic system, self-reported 
affective state) in a specific context (e.g., reproductive hormonal state). The RDoC initiative, 
therefore, allows researchers to go beyond the DSM criteria to identify women who 
demonstrate patterns affective dysregulation related to reproductive states and examine the 
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underlying neurobiological pathophysiology. For example, while some previous studies 
have strictly defined PPD according to the DSM criteria, most have used more inclusive 
criteria, including episodes of depression that began before or during pregnancy and carried 
over into the postpartum and episodes with an onset several months following delivery. A 
study by Forty and colleagues28 demonstrated that defining PPD onset within 8 weeks of 
delivery is optimal for studying the biological triggering of affective dysregulation. Using 
this definition, Deligiannidis et al.29 identified functional neural correlates of postpartum 
depressive symptoms that occur in the context of changing reproductive hormone and 
neurosteroid levels.
Biological Models of PPD in Humans
Reproductive Hormone Model of PPD
Many have hypothesized a role for reproductive hormones in PPD because of the temporal 
association between the substantial and rapid changes in hormone concentrations that occur 
at delivery and the onset of depressive symptoms11. However, there are several important 
reasons for hypothesizing that reproductive hormones play a role in PPD. First, reproductive 
hormones play a major role in basic emotion processing, arousal, cognition, and motivation, 
and thus, may contribute to PPD indirectly by influencing the psychological and social risk 
factors. However, reproductive hormones also regulate each of the biological systems 
implicated in major depression, which suggests that hormones may impact a woman’s risk 
for PPD directly. In the forebrain and hippocampus, ovariectomy decreases and estradiol 
increases brain-derived neurotrophic factor (BDNF) levels30, which are decreased by 
depression and stress and increased by antidepressants31. Estradiol also increases cAMP 
response element-binding (CREB) protein activity32 and the neurotrophin receptor protein 
trkA33, and it decreases GSK-3 beta activity34 in the rat brain similar to antidepressant 
medications. Progesterone also regulates neurotransmitter synthesis, release, and transport35. 
For example, progesterone up-regulates BDNF expression in the hippocampus and cerebral 
cortex36. The relevance of gonadal steroids to affective regulation is further suggested by 
modulatory effects on stress and the HPA axis, neuroplasticity, cellular energetics, immune 
activation, and cortical activity37, all processes that have been implicated as dysfunctional in 
depression.
Of particular note are the manifold effects of gonadal steroids on brain function as revealed 
by brain imaging studies. These studies, employing positron emission tomography (PET) or 
functional magnetic resonance imaging (fMRI) in asymptomatic women, have demonstrated 
that physiologic levels of gonadal steroids modulate the neurocircuitry involved in normal 
and pathological affective states. In a study of healthy women, regional cerebral blood flow 
(rCBF) was attenuated in the dorsolateral prefrontal cortex, inferior parietal lobule, and 
posterior inferior temporal cortex during GnRH agonist-induced hypogonadism, whereas the 
characteristic pattern of cortical activation reemerged during both estradiol and progesterone 
addback38. Studies of neural activity during the menstrual cycle have compared activation 
across menstrual phases within subjects. Goldstein and colleagues39 found increased 
amygdala activity during the late follicular phase (higher estradiol levels) compared to the 
early follicular phase (lower estradiol levels), and Protopopescu et al.40 demonstrated 
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increased activity in the medial orbitofrontal cortex (a region that exerts inhibitory control 
over amygdalar function) during the luteal phase (higher estradiol levels) compared with the 
follicular phase (relatively lower estradiol levels). The opposite was true for the lateral 
orbitofrontal cortex, suggesting that sensory and evaluative neural functions are suppressed 
in the days prior to menstruation40. Ovarian hormones also modulate neural reward function 
in humans, with increased activation of the superior orbitofrontal cortex and amygdala 
during reward anticipation and of the midbrain, striatum, and left ventrolateral prefrontal 
cortex during reward delivery in the follicular phase (compared with the luteal phase)41. 
Thus, there is evidence that reproductive hormones influence the biological systems and 
neural circuits implicated in depression directly, suggesting that the hormone instability 
inherent in the perinatal period could contribute to mood dysregulation in PPD.
Alternative Biological Models
The hormonal changes of pregnancy and the postpartum period do not occur in isolation: 
several other biological systems are altered during pregnancy and have been implicated in 
PPD. Alterations in any of these systems may provoke PPD independent of the changing 
hormonal milieu, which would suggest that there are a number of PPD phenotypes, each 
with their own relevant biomarkers. Thus far, the search for one biomarker for the general 
category of PPD has been elusive, and further research is needed to determine whether there 
are multiple PPD phenotypes with distinct etiologies. It also stands to reason that 
perturbations of other biological systems act in concert with rapidly changing hormone 
levels to contribute to affective dysregulation. Indeed, reproductive hormones have been 
shown modulate all of the other biological systems implicated in PPD: thyroid function42, 
lactogenic function43, the hypothalamic-pituitary-adrenal (HPA) axis44,45, and the immune 
system46. As such, we will discuss the potential contribution of each of these systems to 
affective dysregulation during pregnancy and the postpartum period, and we will discuss the 
evidence of a genetic susceptibility to PPD.
Thyroid hormones have been proposed as a biomarker of PPD in large part because of the 
presumed relationship between thyroid dysfunction and major depression47: depression 
accompanies thyroid pathologies48,49, thyroid dysregulation accompanies depression50,51, 
and the administration of thyroid hormones is thought to augment and accelerate 
antidepressant treatment52,53. Estrogen increases thyroxine-binding globulin (TBG) and 
consequently increases circulating thyroxine (T4) levels54,55. Thyroid dysfunction is 
associated with pregnancy56 and may contribute to PPD in some women57,58. However, 
previous studies have failed to detect a clear association between thyroid hormone 
dysregulation and PPD in the majority of patients59–61.
The lactogenic hormones oxytocin and prolactin have been implicated in PPD62. Failed 
lactation and PPD commonly co-occur, and lactogenic hormones regulate not only the 
synthesis and secretion of breast milk, but also maternal behavior and mood. Oxytocin, in 
particular, may account for the shared pathogenesis of unplanned early weaning and PPD63. 
Estrogen and progesterone modulate oxytocin mRNA expression in brain regions associated 
with maternal behavior and lactation64,65. Lower oxytocin levels during the third trimester 
are associated with increased depressive symptoms during pregnancy63 and the immediate 
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postpartum period66. In a recent study by Stuebe and colleagues63, oxytocin secretion during 
breastfeeding was inversely associated with depression and anxiety symptoms at 8 weeks 
postpartum. Although depression and anxiety symptoms were not associated with 
breastfeeding success in this study, reduced oxytocin may predispose women to PPD and 
subsequently lead to unsuccessful breastfeeding. Moreover, low oxytocin levels in mothers 
with PPD are associated with low oxytocin levels in fathers and their children, suggesting a 
potential neuroendocrine mechanism for the increased risk of depression in children of 
depressed mothers67. Lastly, oxytocin has also been examined as a potential treatment for a 
wide range of psychiatric disorders, including PPD, but with inconsistent findings to 
date68,69.
Hypothalamic-pituitary-adrenal (HPA) axis dysfunction has also been implicated in the 
pathogenesis of PPD. HPA axis hyperactivity is one of the most consistent findings in the 
neuroendocrinology of depression70. Hypercortisolism is associated with depressive 
symptoms and corrected with antidepressant treatment70. Additionally, the HPA axis is 
dysregulated by stress and trauma71, both of which are known precipitants of PPD13,72,73. 
Levels of corticotropin-releasing hormone (CRH), ACTH, and cortisol increase substantially 
during pregnancy and drop four days following delivery74. HPA axis function normalizes at 
approximately 12 weeks postpartum74. The effects of pregnancy on HPA axis function may 
be at least partially attributable to the effects of estrogen on corticosteroid binding 
globulin75, CRH gene expression76, and circulating corticotropin concentrations44. Similar 
to the HPA axis dysregulation seen in nonpuerperal depression, basal concentrations of 
plasma cortisol are increased in women with PPD, and suppression of cortisol by 
dexamethasone is blunted59. In one study, for women with PPD there was no association 
between ACTH and cortisol levels in response to a stress test, whereas among non-
depressed control women, there was a more regulated association with cortisol levels rising 
following the increase in ACTH77. Some evidence suggests that higher cortisol levels at the 
end of pregnancy are associated with increased blues symptoms78. However, it remains 
unclear whether HPA dysregulation contributes to the onset of PPD or occurs as an 
epiphenomenon.
Immune dysregulation has been hypothesized to contribute to the development of PPD79. 
During pregnancy, anti-inflammatory cytokines responsible for immunosuppression are 
elevated and promote pregnancy maintenance, whereas proinflammatory cytokines are 
downregulated. Delivery abruptly shifts the immune system into a proinflammatory state, 
which lasts for several weeks. Patients with depression tend to have higher levels of the 
proinflammatory cytokines tumor necrosis factor (TNF)-α and interleukin (IL)-680, and 
administration of cytokines is associated with the onset of depression81. The immune axis is 
regulated by estradiol. Estradiol modulates cytokine production, cytokine receptor 
expression, activation of effector cells, both the number and function of dendritic cells and 
antigen presenting cells, and monocyte and macrophage immune function82. Differential 
patterns of gene expression that are functionally related to differences in immunity have 
been found to distinguish women with PPD from those without83. Although one recent study 
identified several prenatal immune markers of PPD84, other studies have failed to detect an 
association between immune dysfunction and postpartum depressive symptoms85–87. Thus, 
the role of immune function in PPD remains unclear.
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Evidence of a genetic vulnerability to PPD has emerged from family, candidate gene, 
genome-wide, and gene manipulation studies. Family and twin studies suggest that PPD 
aggregates in families28,88, is heritable89, and may be genetically distinct from nonpuerperal 
depression89. Although multiple genes likely contribute to PPD, the role of specific genetic 
variations remains unclear. Candidate gene studies of PPD have identified several of the 
same polymorphisms implicated in non-puerperal depression, including the Val66Met 
polymorphism of the BDNF gene90,91, the Val158Met polymorphism of the COMT 
gene92,93(p-), the BcII polymorphism of the glucocorticoid receptor and the rs242939 
polymorphism of the CRH receptor 194, the short version of the serotonin-transporter linked 
polymorphic region (5-HTTLPR) genotype95,96, three polymorphisms in the serotonin 2A 
receptor (HTR2A) gene97, and three polymorphisms at protein kinase C, beta (PRKCB)98. 
There is also evidence of PPD biomarkers that are theoretically distinct from those of MDD 
and that implicate reproductive hormones. For example, polymorphisms in the estrogen 
receptor alpha gene (ESR1) have been found to be associated with PPD98,99. However, to 
date, the results of candidate gene studies of MDD and PPD have failed to replicate100, have 
not been statistically significant after correcting for multiple comparisons97,98, and there is 
little consistency in the specific polymorphisms tested and identified across studies, which 
means that any one genetic variant or set of genetic variants is of limited utility as a 
diagnostic indicator. Genomic studies aim to address some of these shortcomings, and there 
have been a few small genomic studies of PPD to date. In a genome-wide linkage study of 
1,210 women, researchers identified genetic variations on chromosomes 1q21.3-q32.1 and 
9p24.3-p22.3 that may increase susceptibility to PPD101. Of particular relevance here, the 
strongest implicated gene was Hemicentin 1 (HMCN1), which contains multiple estrogen 
binding sites. Although the results were no longer significant after accounting for multiple 
comparisons101, the association between the rs2891230 polymorphism of the HMCN1 gene 
and PPD was confirmed by a subsequent candidate gene study102. Similarly, a genome-wide 
association study yielded a third-trimester biomarker panel of 116 transcripts that predicted 
PPD onset with 88% accuracy in both the discovery sample of 62 women and the 
independent replication sample of 24 women103. Of these transcripts, ESR1 was the only 
enriched transcription factor binding site, again potentially implicating estrogen in the 
pathogenesis of PPD103. Estrogen-induced DNA methylation change has also been 
implicated in PPD, which suggests that women with PPD have an enhanced sensitivity to 
estrogen-based DNA methylation reprogramming104. In order to serve as reliable 
biomarkers of PPD, these genetic variants will require replication in larger, independent 
samples, which is currently an active area of investigation in the field.
Reproductive Hormone Models of PPD in Rodents
Non-human animal studies largely support the role of reproductive hormones in PPD. 
Ovariectomized rats treated with 17β-estradiol and progesterone followed by vehicle only, to 
induce a hormone withdrawal state similar to the rodent postpartum period, show increased 
immobility during the forced swim test4,7, a behavioral indicator of despair, and decreased 
sucrose consumption and preference105, a behavioral indicator of anhedonia. One recent 
study demonstrated that estradiol supplementation and withdrawal alone was sufficient to 
provoke immobility during the forced swim test and anhedonic behavior during lateral 
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hypothalamic self-stimulation18. Increased depression-like behavior during the “postpartum” 
demonstrated in previous studies could therefore be attributed to estradiol withdrawal alone.
The effects of estradiol withdrawal on depressive behavior in non-human animals are well 
documented. Following bilateral ovariectomy, rats demonstrate increased immobility during 
the forced swim test, and these effects are reversed by treatment with estradiol alone106,107. 
In addition, reduced immobility following a single administration of estradiol lasts 2–3 days, 
and the behavioral effects are the same as those following fluoxetine treatment108. The 
antidepressant effects of estradiol during the forced swim test appear to involve selective 
actions at intracellular estrogen receptor-β (ERβ) in the ventral tegmental area109 and, in 
fact, may require ERβ110. In addition, abrupt estradiol withdrawal following sustained high 
estradiol levels results in elevated brain cortical dehydroepiandrosterone sulfate (DHEA-S), 
a neuroactive steroid synthesized endogenously in the brain that attenuates GABA-ergic 
activity and may be relevant to postpartum depressive symptoms111. Chronic administration 
of estradiol leads to dopamine receptor up-regulation and increased presynaptic dopamine 
activity in the striatum112–114, which, when followed by abrupt estradiol withdrawal, leads 
to dysregulation in brain dopaminergic pathways and depressive symptoms115.
Estradiol-withdrawal models of PPD have two weaknesses: 1) they have low face validity as 
models of PPD given that the human postpartum period is characterized by a drop in both 
estradiol and progesterone (whereas progesterone drops before delivery in rodents), and 2) 
they result in depression without the attendant anxiety often seen in women with PPD116. 
The addition of progesterone to hormone withdrawal models of PPD is relevant given that 
progesterone withdrawal provokes anxiety. As noted above, progesterone metabolites act on 
GABA receptors in the brain, producing sedative-like effects by enhancing GABA 
neurotransmission117. Abrupt decreases in progesterone are associated with anxiety118, and 
treatment with progesterone reduces anxiety119. The anxiolytic effects of progesterone 
appear to be mediated by the progesterone metabolite allopregnanolone (ALLO)120. Indeed, 
postpartum rats show increased depressive behavior (increased immobility, decreased 
struggling and swimming) compared with pregnant rats, and this affect appears to be 
mediated by low hippocampal ALLO levels during the postpartum period120.
To examine the effects of concurrent estradiol and progesterone withdrawal, Suda et al.8 
created a novel rodent model of PPD by administering hormone levels more consistent with 
human pregnancy than rat pregnancy. The concurrent withdrawal of estradiol and 
progesterone resulted in decreased immobility during the forced swim test (i.e., less 
depression-like behavior); however, it also resulted in learned helplessness, which was 
indicated by a failure to avoid repeated foot shocks8. Animals in this study also showed 
increased anxiety. Taken together, the existing animal models suggest that the abrupt 
withdrawal of estradiol alone produces behavioral despair and anhedonia, whereas the 
concurrent withdrawal of progesterone and estradiol produces learned helplessness and 
anxiety. However, these studies do not explain how the same putative stimulus (i.e., 
hormone change) is capable of causing depression in some women and not others.
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Fluctuating Reproductive Hormone Levels Trigger PPD
There is no consistent or convincing evidence that women who develop PPD experience 
more rapid postpartum hormone withdrawal, have lower reproductive hormone 
concentrations during the postpartum period, or experience greater reductions in hormone 
levels from pregnancy to the postpartum than women without PPD9–11,29,121. The onset of 
depressive symptoms, however, is temporally coincident with the rapid changes in estradiol 
and progesterone levels that occur at delivery, leading some researchers to view the change 
in reproductive hormones as a potent stressor in susceptible women11.
Evidence that a subgroup of women are vulnerable to perinatal changes in reproductive 
hormones comes from treatment studies examining the effects of administering exogenous 
estradiol to women at high risk for PPD or those with active PPD symptoms. In a pilot study 
of 11 women with a history of PPD and no other history of affective disorder, participants 
were prophylactically administered oral Premarin, a conjugated estrogen, immediately 
following delivery to prevent estrogen withdrawal and the onset of depressive symptoms6. 
Ten of the 11 women remained well during the postpartum and for the first year following 
delivery6. A later double-blind, placebo-controlled study of 61 women with PPD that began 
within three months following delivery, showed that women treated with estradiol (n=34) 
(delivered via a transdermal patch) improved significantly more than women who received 
placebo (n=27), although nearly half of the women in both groups were also taking 
antidepressant medication5. A subsequent study examined the effects of estradiol treatment 
on a group of 23 women with severe postpartum depression, many of whom had attempted 
treatment with antidepressant medication or psychotherapy without effect12. At baseline, 16 
of the 23 patients had serum estradiol concentrations consistent with gonadal failure. All 
women in the study received sublingual estradiol treatment for 8 weeks. After the first week, 
depressive symptoms significantly decreased, and by the end of the eight weeks all patients 
had achieved depressive symptom scores consistent with clinical recovery. Although 
Ahokas et al.12 suggest that postpartum “gonadal failure” is a risk factor for PPD, they did 
not compare estradiol levels in women with and without PPD. Instead, their data support the 
notion that, in susceptible women, low or declining estradiol levels may trigger PPD, while 
stable or increasing estradiol levels may ameliorate depressive symptoms. Although these 
treatment studies suggest a role for estradiol in the pathogenesis of PPD, they are small, 
lacking control groups, and confounded by the effects of stress, lack of sleep, and 
homeostatic shifts attendant to childbirth.
In order to assess the role of reproductive hormones in PPD directly, Bloch et al.3 created a 
scaled-down hormonal model of the puerperium wherein euthymic women with or without a 
history of PPD were blindly administered high-dose estradiol and progesterone during 
ovarian suppression and then abruptly withdrawn. Women with a history of PPD showed 
increasing depressive symptoms during hormone addback and further exacerbation during 
hormone withdrawal, but women lacking a history of PPD experienced no perturbation of 
mood despite identical hormonal conditions. Increasing depressive symptoms during both 
hormone addback and withdrawal among those with a history of PPD is consistent with 
research demonstrating that one of the biggest risk factors for PPD is depression during 
pregnancy15. The advantage of this design is that the effects of reproductive hormones on 
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mood were examined without the confounding biological and psychosocial stressors 
associated with childbirth. The results provide support for a hormone-sensitive PPD 
phenotype in which reproductive hormone change alone is sufficient to provoke mood 
dysregulation in otherwise euthymic women.
Some have hypothesized that the source of PPD vulnerability is in abnormal neural 
responses to the normal perinatal fluctuations in reproductive hormones. PPD is 
characterized by abnormal activation of the same brain regions implicated in non-puerperal 
major depression: the amygdala, insula, striatum, orbitofrontal cortex, and dorsomedial 
prefrontal cortex122–124. PPD is also associated with reduced connectivity between the 
amygdala and prefrontal regions, which implicates dysregulation of the limbic system in the 
neural pathophysiology of PPD123. Despite similar levels of circulating progesterone and 
ALLO to controls, women with PPD also show reduced resting state functional connectivity 
between the anterior cingulate cortex, amygdala, hippocampus, and dorsolateral prefrontal 
cortex in the context of the postnatal decline progesterone and ALLO29. These 
neuroimaging studies suggest that the neural abnormalities associated with PPD are unique 
to the perinatal period and may be unmasked by changes in circulating reproductive 
hormone concentrations. Taken together, the results of the human studies are suggestive of a 
hormone-sensitive PPD phenotype characterized by neural abnormalities present during the 
puerperium when reproductive hormone concentrations change rapidly.
One potential mechanism by which changing reproductive hormone levels trigger PPD 
involves neurosteroid regulation of affect. Neurosteroids are metabolites of steroid 
hormones that are synthesized in the brain and nervous system and modulate γ-aminobutyric 
acid (GABA) and glutamate. Two neurosteroids in particular play a role in affective 
dysregulation: dehydroepiandrosterone (DHEA) and ALLO. Abnormal DHEA secretion has 
been implicated in major depression 126–130, and DHEA is an effective antidepressant in 
both men and women131,132. The majority of research on neurosteroids in reproductive 
mood disorders, however, has focused on the progesterone metabolite ALLO. There are 
several reasons to speculate that ALLO plays a role in PPD. ALLO modulates the GABA 
receptor, which mediates anxiolysis133. ALLO supplementation has anxiolytic 
effects134–136, whereas ALLO withdrawal produces anxiety and insensitivity to 
benzodiazepines118,137. ALLO levels are decreased in depression and increased with 
successful antidepressant treatment138–143. ALLO also modulates the biological processes 
dysregulated in major depressive disorder, including HPA axis regulation144–147, 
neuroprotection148,149, and immune function150. ALLO also regulates the neural circuits 
implicated in depression, including the limbic system151,152.
Cortical GABA and ALLO are reduced in postpartum women, regardless of the presence of 
PPD, compared with healthy women in the follicular phase153. Although there is no 
evidence of abnormalities in basal circulating ALLO levels in PPD, women with PPD show 
reduced resting state functional connectivity between the anterior cingulate cortex, 
amygdala, hippocampus, and dorsolateral prefrontal cortex in the context of the postnatal 
decline in ALLO29. In addition, we recently reported an association between changes in 
ALLO levels and depressive symptoms during GnRH agonist-induced ovarian suppression 
and ovarian steroid addback in women with a history of PPD but not in those without such a 
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history154. These studies suggest that, even in the presence of normal absolute levels, 
perinatal fluctuations in reproductive hormones may precipitate symptoms in a vulnerable 
subpopulation of women as a result of changing ALLO levels.
The identification of biomarkers in humans is difficult because of a lack of experimental 
control over the patient’s environment and genetic background and inaccessibility of brain 
tissue required for analysis. Gene manipulation studies in non-human animals can help 
model how genetic variants and the environment interact to yield a distinct behavioral 
phenotypes155. Animal models that have demonstrated that the behavioral effects of 
maternal care are associated with gene expression changes that persist into adulthood and 
can be transmitted across generations provide a potent epigenetic model of PPD155. For 
example, estradiol withdrawal is clearly associated with estradiol-reversible anxiety in a 
strain-dependent fashion (Schoenrock et al., unpublished manuscript). One genetic knockout 
model potentially explains both the specificity of affective dysregulation during the perinatal 
period and also the variation in susceptibility to PPD among women 125. In this model, 
Maguire and Mody125 demonstrated a GABAA receptor subunit knockout that is 
behaviorally silent until an animal is exposed to pregnancy and the postpartum state, 
following which the dam displays depression-like behavior and cannibalizes its young. 
Thus, reproductive events may unmask the genetic susceptibility to affective dysregulation. 
Maguire and Mody125,156,157 observed that alterations in the GABAA receptor δ-subunit 
occur as ovarian hormone levels fluctuate during the menstrual cycle, pregnancy, and the 
postpartum period. During pregnancy, the expression of the GABAA receptor δ-subunit is 
downregulated as ALLO levels increase, and at parturition, the expression of the GABAA 
receptor δ-subunit recovers in response to rapidly declining neurosteroid levels157. The 
failure to regulate these receptors during pregnancy and the postpartum, consequent to the 
knockout of the GABAA receptor δ-subunit, appears to provoke behavioral abnormalities 
consistent with PPD. Thus, as noted above, GABAA receptor δ-subunit deficient mice 
exhibit normal behaviors prior to pregnancy, but they show insensitivity to ALLO during 
pregnancy, depression-like and anxiety-like behavior, and abnormal maternal behavior125. 
This model suggests that changes in reproductive hormone concentrations during pregnancy 
and the postpartum are capable of provoking affective dysregulation, particularly in those 
with a genetically determined susceptibility.
Conclusion
The cross-species role of reproductive hormones in depressive behavior suggests a 
neuroendocrine pathophysiology for PPD. PPD, as defined in contemporary research, 
includes depression that began during or before pregnancy; depression that occurred in the 
context of a childhood trauma history, traumatic labor or delivery, subthreshold thyroid 
dysfunction, psychosocial stress, or sleep deprivation; and depression that co-occurred with 
obsessive-compulsive disorder, PTSD, generalized anxiety disorder, or personality 
pathology. Logic would preclude consideration of all of these as the same disorder; 
consequently, when attempting to understand the contribution of hormonal signaling to 
postpartum affective dysregulation, it is therefore necessary to carefully define the study 
population and attempt to characterize and disentangle individual PPD phenotypes. The 
extant literature supports the existence of a hormone-sensitive PPD phenotype3. In order to 
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study the clinical and neuroendocrine correlates of this phenotype, some researchers have 
selected women with a history of PPD and without a history of non-puerperal depressive 
episodes3,18. Although these studies are primarily relevant for understanding the risk of PPD 
recurrence, they represent the first step toward identifying factors that predict first onset 
PPD. There is sufficient evidence to suggest that reproductive hormone fluctuations trigger 
affective dysregulation in sensitive women. Even within the hormone-sensitive phenotype, 
alterations in multiple biological systems — the immune system, HPA axis, and lactogenic 
hormones — likely contribute to the pathophysiology of PPD. Studies are underway to 
disentangle the complex interplay of fluctuating reproductive hormones, neurosteroids, HPA 
axis reactivity, neural dysfunction, and genetics with a specific focus on identifying 
genomic, brain, and behavior relationships that contribute to affective dysfunction in the 
context of specific reproductive states. Consistent with the RDoC mission, this line of 
research represents not only an opportunity to identify novel treatment targets for PPD but 
also—critically—the potential to prevent PPD in susceptible women.
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